用于治疗急性细菌性皮肤及皮肤结构感染的新型脂糖肽类药物。

Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.

作者信息

Bell Allison M, King S Travis, Barber Katie E, Adcock Kim G, Wagner Jamie L, Stover Kayla R

机构信息

Allison Bell is an associate professor in the Division of Pharmacy Practice and Administrative Sciences at the Univeristy of Cincinnati James L. Winkle College of Pharmacy in Cincinnati, Ohio. S. Travis King is a Clinical Pharmacy Specialist in Infectious Diseases at Ochsner Medical Center in New Orleans, Louisiana. Katie E. Barber is an assistant professor in the Department of Pharmacy Practice at the University of Mississippi School of Pharmacy, Jackson, Miss. Kim G. Adcock is a professor in the Department of Pediatrics at the University of Mississippi Medical Center, Jackson, Miss., and a professor in the Department of Pharmacy Practice at the University of Mississippi School of Pharmacy, Jackson, Miss. Jamie L. Wagner is a clinical assistant professor in the Department of Pharmacy Practice at the University of Mississippi School of Pharmacy, Jackson, Miss. Kayla R. Stover is an associate professor in the Department of Pharmacy Practice at the University of Mississippi School of Pharmacy, Jackson, Miss.

出版信息

Nurse Pract. 2018 Oct;43(10):31-37. doi: 10.1097/01.NPR.0000544995.21102.7f.

DOI:10.1097/01.NPR.0000544995.21102.7f

PMID:30153191

Abstract

Acute bacterial skin and skin structure infections (ABSSSIs) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSIs are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, the two newest lipoglycopeptides, in the context of the other available I.V. infusion standard therapy options.

摘要

急性细菌性皮肤及皮肤结构感染（ABSSSIs）是全球最常见的感染类型之一。因ABSSSIs导致的住院与高死亡率相关。本文在其他可用的静脉输注标准治疗方案的背景下，讨论了两种最新的脂糖肽类药物奥利万星和达巴万星的作用。